| Autor: |
Hideto Tamura, Rimpei Morita, Koiti Inokuchi, Mika Sunakawa-Kii, Hiroshi Handa, Takumi Ito, Junichi Yamamoto, Mariko Ishibashi |
| Rok vydání: |
2023 |
| Popis: |
Supplementary Materials and methods; Supplementary Table S1: Cell characteristics and phenotypes of MM cell lines; Supplementary Table S2: Characteristics of patients with newly diagnosed MM in Figure 1H; Supplementary Table S3: Primer and shRNA sequence; Supplementary Table S4: Four hundred four genes differentially expressed in MM cell lines treated with or without POM; Supplementary Figure S1: Antitumor effect of LEN and POM on MM cell lines; Supplementary Figure S2: Relationship of POM sensitivity with CRBN expression; Supplementary Figure S3: DNA copy numbers of PD-L1 in MM cell lines; Supplementary Figure S4: The level of cell-surface expression of PD-L2; Supplementary Figure S5: Cell-surface expression of BCMA and TACI on MM cell lines treated with IMiDs; Supplementary Figure S6: Enrichment plots for the gene sets of the MAPK/ERK pathway; Supplementary Figure S7: In vivo analysis using a murine xenograft model of human myeloma MM.1S cells inoculated into the flanks of NOG mice; Supplementary Figure S8: PD-L1 mRNA expression in CRBN-knockout and Ikaros- and Aiolos-knockdown cells after 3-day cultivation with LEN or POM; Supplementary Figure S9: Ikaros binding sites in the promoter of the PD-L1 gene; Supplementary Figure S10: Cell proliferation and T-cell activation of CD8+ T cells on day 4 when co-cultivation of T cells with untreated or LEN-pretreated U266 cells was treated with durvalumab and LEN; Supplementary Figure S11: APRIL protein and mRNA expression in CRBN-knockout and Ikaros- and Aiolos-knockdown MOSTI-1 cells after 3-day cultivation with LEN or POM. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
